• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >Glycogen synthase kinase-3 - a promising therapeutic target: Dr Hagit Eldar-Finkelman interviewed by Emma Quigley.
【24h】

Glycogen synthase kinase-3 - a promising therapeutic target: Dr Hagit Eldar-Finkelman interviewed by Emma Quigley.

机译：糖原合酶激酶3-一种有希望的治疗靶标：艾吉·奎格利（Hamma Eldar-Finkelman）接受艾玛·奎格利（Emma Quigley）的采访。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Dr Hagit Eldar-Finkelman (Sackler School of Medicine, Israel) was interviewed by Emma Quigley (Commissioning Editor, Expert Opinion on Therapeutic Targets) on 16th February 2006. Born in Jerusalem, Dr Eldar-Finkelman received her BSc in Chemistry in 1984 and both her MSc in Physical Chemistry (1986) and PhD in Life Science (1993) from the Weizmann Institute of Science. She was a recipient of the British Council Award, which allowed her to conduct research in biological nuclear magnetic resonance at the University of Oxford in the laboratory of Professor George K Radda. Following postdoctoral work at the School of Medicine of the University of Washington with Nobel Laureate Professor Edwin G Krebs, she became an Assistant Professor in the Department of Medicine at Harvard Medical School. Dr Eldar-Finkelman joined the Sackler School of Medicine at Tel Aviv University in 1999. Dr Eldar-Finkelman's research focuses on the molecular mechanisms regulating the protein kinase glycogen synthase kinase-3 (GSK-3), and their implications in negative regulation of signalling pathways. In particular, her work aims to develop specific inhibitors for GSK-3 and to test their functions in vitro and in vivo, considering the concept that such inhibitors may be useful in insulin resistance and Type 2 diabetes. These studies provide a conceptual basis for development of GSK-3 inhibitors and may lead to design of small molecules for treatment of diabetes and or neurodegenerative disorders.
机译：Hagit Eldar-Finkelman博士（以色列萨克勒医学院）于2006年2月16日接受了Emma Quigley（治疗目标专家意见的委托编辑）的采访。Eldar-Finkelman博士出生于耶路撒冷，于1984年获得化学学士学位她在魏兹曼科学研究所获得物理化学硕士学位（1986）和生命科学博士学位（1993）。她曾获得英国文化协会奖，这使她得以在牛津大学的乔治·K·拉达教授的实验室中进行生物核磁共振研究。在华盛顿大学医学院的博士后工作中，诺贝尔奖获得者埃德温·克雷布斯（Edwin G Krebs）教授之后，她成为哈佛医学院医学院的助理教授。 Eldar-Finkelman博士于1999年加入特拉维夫大学萨克勒医学院。Eldar-Finkelman博士的研究重点在于调节蛋白激酶糖原合酶激酶3（GSK-3）的分子机制及其对信号负调控的意义。途径。特别是，考虑到这种抑制剂可用于胰岛素抵抗和2型糖尿病的概念，她的工作旨在开发GSK-3的特异性抑制剂并在体外和体内测试其功能。这些研究为开发GSK-3抑制剂提供了概念基础，并可能导致设计用于治疗糖尿病和/或神经退行性疾病的小分子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号